Results 181 to 190 of about 1,476,364 (294)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Cardiac atrophy associated to cancer: new perspectives in signaling pathways. [PDF]

Mol Biomed
Lodeiro AC, Leal-López S, Costas-Abalde S, Debasa-Corral L, Otero-Fraga MJ, Vilar J, Ait-Oufella H, Pazos Y, Camiña JP, Santos-Zas I.   +9 more
europepmc   +1 more source

Cyclosporine A ameliorates ulcerative colitis by inhibiting cellular senescence, modulating the JAK2-STAT3/NF-κB signaling pathway, and regulating the gut microbiota-metabolite axis

Bingxiang Zhao, Yingjie Xu, Fuxing Li, Shujia Song, Zhenlin Liu, Jiayu Liu, Zhengze Liu, X. Peter Chen, xiao bo Wang, Hui Zhou, Linlin Zhao   +10 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Foam cells: tracing the diverse cellular origins and their linked signaling pathways. [PDF]

J Transl Med
Jiao X, Guo D, Li W, Li S, Shao G, Shen T, Yu X.   +6 more
europepmc   +1 more source

The Human Adenovirus Type 5 E4orf4 Protein Targets Two Phosphatase Regulators of the Hippo Signaling Pathway [PDF]

, 2015
Melissa Z. Mui, Yiwang Zhou, Paola Blanchette, Naila Chughtai, Jennifer F. Knight, Tina Gruosso, Andreas I. Papadakis, Sidong Huang, Morag Park, Anne‐Claude Gingras, Philip E. Branton   +10 more
openalex   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Electroacupuncture ameliorates ulcerative colitis by suppressing ferroptosis via the JAK2/STAT3 signaling pathway

Tao Zhu, Hong-ye Wan, Zhengyang Qu, Hongkai Zhu, Laixi Ji, Jing Zhang   +5 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Aberrant Signaling Pathways in Squamous Cell Lung Carcinoma

Cancer Informatics, 2011
Ivy Shi,, Nooshin Hashemi Sadraei, Zhong-Hui Duan, Ting Shi   +3 more
doaj